INT41
/ Vybion
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
September 09, 2025
Estimated cost-savings from integrated care for HIV, diabetes and hypertension in sub-Saharan Africa: a cost-minimisation analysis.
(PubMed, Glob Health Action)
- "From a societal perspective, integrated care for participants with multiple conditions generated mean cost-savings of Int$41.54 (95%CI 29.42-53.67, p < 0.0001) per patient-visit. Integrated care is cost-saving from a societal perspective and should be considered for scale-up in Tanzania, Uganda and similar settings. ISRCTN43896688."
HEOR • Journal • Cardiovascular • Diabetes • Human Immunodeficiency Virus • Hypertension • Infectious Disease • Metabolic Disorders
July 29, 2023
"Challenge accepted. I nominate @FJ_III @CoachDintz41 . Bigger than baseball! @AmericanCancer https://t.co/MhYhQktaZR"
(@jbasile281)
Oncology
March 15, 2021
[VIRTUAL] SCURVY IS PREVALENT IN PATIENTS PRESENTING WITH UPPER GASTROINTESTINAL BLEEDING AND PREDICTS INCREASED MORTALITY AND ADVERSE CLINICAL OUTCOMES: A PROSPECTIVE AUSTRALIAN COHORT STUDY
(DDW 2021)
- "No differences in ICU admission, transfusion requirements, LOS or AIMS65 score were noted.In non-variceal UGIB (n=123), VCD was associated with higher mortality (5.6% vs. 0%, p=0.03) and AEs (composite endpoint 41.7% vs. 24.1%, p=0.05)... VCD is prevalent in patients with UGIB and associated with significantly higher mortality and AEs. Further studies are required to determine the impact of early Vitamin C supplementation following UGIB."
Adverse events • Clinical • Clinical data • Critical care • Gastroenterology • Gastrointestinal Disorder • Infectious Disease • Novel Coronavirus Disease • Peptic Ulcer • Pneumonia • Respiratory Diseases • Septic Shock
1 to 3
Of
3
Go to page
1